KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

West Pharmaceutical Services (WST) EBT (2016 - 2025)

West Pharmaceutical Services' EBT history spans 17 years, with the latest figure at $161.5 million for Q4 2025.

  • For Q4 2025, EBT fell 2.06% year-over-year to $161.5 million; the TTM value through Dec 2025 reached $600.9 million, up 2.63%, while the annual FY2025 figure was $600.9 million, 2.63% up from the prior year.
  • EBT for Q4 2025 was $161.5 million at West Pharmaceutical Services, down from $171.9 million in the prior quarter.
  • Across five years, EBT topped out at $227.2 million in Q2 2022 and bottomed at $110.5 million in Q1 2025.
  • The 5-year median for EBT is $166.5 million (2023), against an average of $165.7 million.
  • The largest annual shift saw EBT surged 106.86% in 2021 before it tumbled 30.39% in 2024.
  • A 5-year view of EBT shows it stood at $181.9 million in 2021, then decreased by 29.25% to $128.7 million in 2022, then surged by 30.69% to $168.2 million in 2023, then dropped by 1.96% to $164.9 million in 2024, then fell by 2.06% to $161.5 million in 2025.
  • Per Business Quant, the three most recent readings for WST's EBT are $161.5 million (Q4 2025), $171.9 million (Q3 2025), and $157.0 million (Q2 2025).